FEops, a startup accelerated by the 3DEXPERIENCE Lab, advancing personalized care in structural heart disease

Challenge

Structural heart interventions remain highly complex, with outcomes often depending on how devices interact with each patient’s unique anatomy. Traditional approaches rely on basic anatomical measurements, which are insufficient to predict device behavior and patient response. This creates challenges for both manufacturers, who face long development timelines, and physicians, who need better tools to optimize treatment decisions and improve outcomes.

FEops technology for personalized care in structural heart disease

Disruptive Innovation

FEops is redefining structural heart interventions with cutting-edge technology that transforms cardiac images into digital twins—virtual copies of the heart or its substructures. This approach enables highly personalized treatment planning, helping physicians and MedTech companies alike make better decisions, reduce risks, and accelerate innovation.

At the core is the CE-marked FEops HEARTguide™, a unique, cloud-based platform that goes beyond traditional anatomical measurement. By combining digital twins with AI-enabled anatomical analysis, HEARTguide™ delivers data-driven insights that improve procedure planning, efficiency, and outcomes.

Key Innovations

  • Transforming cardiac images into digital twins
    FEops HEARTguide™ simulations provide a detailed preview of how a device will interact with a patient’s anatomy before the procedure. Physicians can determine the optimal size and positioning, reducing complications and improving outcomes.
  • Going beyond simple anatomical measurements
    Unlike manual “rigid-device overlay” techniques, FEops offers deeper insights into device–anatomy interaction, enabling safer and more precise interventions.
  • Validated, AI-enabled anatomical analysis
    FEops HEARTguide™ is the only stand-alone platform that merges digital twins with AI to provide consistent, quality-controlled data in minutes.

Pipeline Developments

  • Expanding to new interventions
    Beyond TAVI and LAAo planning, FEops is developing personalized simulations for transcatheter tricuspid valve replacement (TTVR) and other structural heart therapies.
  • Enhancing AI algorithms
    Continuous improvements deliver faster, more consistent, and more accurate anatomical analyses.
  • Beyond pre-operative planning
    By fusing FEops simulations with live fluoroscopic images inside the cath lab, physicians will soon be able to position devices with unmatched precision during procedures.
United Nations’ Sustainable Development Goal 3

Impact

By advancing the United Nations Sustainable Development Goal 3: Good Health and Well-Being, FEops contributes to healthier lives and improved care for patients of all ages. Its cloud-based platform, FEops HEARTguide™, leverages predictive simulation to give clinicians and medical device manufacturers unprecedented preoperative insights into how transcatheter structural heart devices will interact with a patient’s unique anatomy. This innovation supports safer procedures, more effective treatments, and better patient outcomes.

FEops innovation to optimize treatment planning, and improve patient outcomes

Leveraging the 3DEXPERIENCE platform

The 3DEXPERIENCE platform provides FEops with the tools needed to scale and optimize its solution. Its on-demand, cloud-based software and hardware ensure seamless and efficient delivery of FEops HEARTguide™ to clinicians worldwide. Advanced 3D multiphysics simulation enables the most accurate and personalized predictive insights into patient-specific device–heart interactions. In addition, the platform offers the potential to integrate data science and machine learning into FEops HEARTguide™ workflows, significantly reducing turnaround times and enhancing overall efficiency.

FEops logo

FEops

FEops is a medtech company advancing personalized care in structural heart disease through predictive simulations. Its cloud-based platform, FEops HEARTguide™, helps clinicians and device manufacturers optimize treatment planning, improve patient outcomes, and accelerate innovation.

Meet the Team

Matthieu De Beule
CEO, co-founder and member of the board of directors
Peter Mortier
CTO, co-founder and member of the board of directors
Isabelle Decroos
CFO
Christian Vincent
Director of therapy development
Nico Uwents
Director of business development

Explore Our Portfolio

Submit Your Application

Interested? Take your chance to elevate your project to the next level.